184 results about "Dilated cardiomyopathy" patented technology

A mitral annuloplasty and left ventricle restriction device is designed to be transvenously advanced and deployed within the coronary sinus and in some embodiments other coronary veins The device places tension on adjacent structures, reducing the diameter and / or limiting expansion of the mitral annulus and / or limiting diastolic expansion of the left ventricle. These effects may be beneficial for patients with dilated cardiomyopathy.

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

Mitral valve prolapse and mitral regurgitation can be treating by implanting in the mitral annulus a transvalvular intraannular band. The band is positioned so that it extends transversely across a coaptive edge formed by the closure of the mitral valve leaflets, to inhibit prolapse into the left atrium. At least one marginal chordae is severed, to permit leaflet closure against the band.

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

Mitral valve prolapse and mitral regurgitation can be treating by implanting in the mitral annulus a transvalvular intraannular band. The band is positioned so that it extends transversely across a coaptive edge formed by the closure of the mitral valve leaflets, to inhibit prolapse into the left atrium. At least one marginal chordae is severed, to permit leaflet closure against the band.

A device is proposed to progressively reduce the hemodynamic cardiac symptoms of congestive heart failure as well as those induced by dilated cardiomyopathies. This device affords progressive diastolic ventricular control by offering a method for percutaneous access and adjustments of its gas filled bladders surrounding the heart. After opening the pericardium, the device is not attached to the heart muscle but may be anchored to the pericardial sac. The device actually extends primarily around the heart from below the atrio-ventricular canal to the cardiac apex. Between the device exterior, made of non-elastic material and the epicardium, two independent elastic bladders or chambers provide variable compressive diastolic support to the right and left ventricles, while allowing adequate blood flow to the anterior and posterior descending epicardial branches of the coronary arteries and veins. Progressive hemodynamic increases in diastolic pressures for the right and left ventricles can be individually and repeatedly monitored by pressure gauges and an inert gas separately injected or removed in the enclosed chest through self-sealing access ports. These ports are subcutaneously implanted in the left anterior axillary line and connected by thin tubes across the 4th or 5th intercostal spaces to the pericardial bladders or chambers described above.

Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and / or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.

The invention relates to BALB / c mice that are deficient in the programmed cell death-1 receptor (PD-1), a screening method for autoimmune disease medicine using these mice, an IgG self-reactive antibody that the mice produce, a protein that specifically reacts to the antibody and is produced in heart, and a diagnostic method for dilated cardiomyopathy using the protein. Because PD-1 deficient BALB / c mice spontaneously develop autoimmune disease, and specifically dilated cardiomyopathy, they are useful for screening for medicines against these diseases.

The invention discloses an LMNA gene knocked-out cell line. The cell line is a 293T cell line or a HePG2 tumor cell line. Cells to be knocked out are transfected by plasmid vectors constructed by twopairs of gRNA as shown in SEQ ID NO. 1-4 or two pairs of gRNA as shown in SEQ ID NO. 7-10 on the basis of a crispr-cas9 technology, and then are subjected to resistance screening to obtain the cell line. The LMNA gene knocked-out cell line can be used for intervention drug screening cell models for diseases such as dilated cardiomyopathy, fat metabolic disorder syndrome and premature aging syndromes.

Cardiomyopathy may be treated by distributing space-occupying agent within the myocardium in a pattern about one or more chambers of the heart, such that the space-modifying agent integrates into and thickens at least part of the cardiac wall about the chamber so as globally to reduce wall stress and stabilize or even reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function. Over time the relief of wall stress reduces oxygen consumption and promotes healing. Moreover, various long-term therapeutic effects may be realized depending on the properties of the space-occupying agent, including combinations with other therapeutic materials. Specific cardiac conditions treatable by these systems and methods include, for example, dilated cardiomyopathy (with or without overt aneurismal formations), congestive heart failure, and ventricular arrhythmias. Patterns of distribution of space-occupying agent within the myocardium for global resizing may also be used or augmented to treat localized conditions such as myocardial infarctions, overt aneurysm of the ventricular wall as typically forms in response to large transmural myocardial infarctions, and mitral regurgitation due to a noncompliant mitral valve. These techniques may also be used to treat localized conditions that may not yet have progressed to cardiomyopathy.

Among the four heart valves, the mitral is the most frequently affected by disease resulting in defective valve opening (stenosis) or incomplete closure (insufficiency). Most often this is due to distortion of the valve apparatus secondary to rheumatic or degenerative disease. These lesions, called “organic” require open heart surgery. In patients with coronary disease or with dilated cardiomyopathy the mitral valve can be insufficient although structurally normal. These valves are “functionally” insufficient. Because of the poor condition of these patients where open heart surgery carries a significant operative risk, less invasive percutaneous alternatives are being explored today. The present novel invention represents a radical departure from other procedures because it repositions the posterior papillary muscle utilizing a device located in the interventricular veins.

Cardiomyopathy may be treated by distributing space-occupying agent within the myocardium in a pattern about one or more chambers of the heart, such that the space-modifying agent integrates into and thickens at least part of the cardiac wall about the chamber so as globally to reduce wall stress and stabilize or even reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function. Over time the relief of wall stress reduces oxygen consumption and promotes healing. Moreover, various long-term therapeutic effects may be realized depending on the properties of the space-occupying agent, including combinations with other therapeutic materials. Specific cardiac conditions treatable by these systems and methods include, for example, dilated cardiomyopathy (with or without overt aneurismal formations), congestive heart failure, and ventricular arrhythmias. Patterns of distribution of space-occupying agent within the myocardium for global resizing may also be used or augmented to treat localized conditions such as myocardial infarctions, overt aneurysm of the ventricular wall as typically forms in response to large transmural myocardial infarctions, and mitral regurgitation due to a noncompliant mitral valve. These techniques may also be used to treat localized conditions that may not yet have progressed to cardiomyopathy.

The invention relates to a multi-scale dilated cardiac muscle segmentation and classification method based on Attention. The method comprises the following steps: collecting a plurality of cases suffering from the dilated cardiomyopathy, and collecting MRI image data of the cardiomyopathy; P; performing artificial edge labeling on the lesion area of the MRI image data collected in the last step layer by layer to serve as label data; carrying out standardized preprocessing on the label data obtained in the previous step and converting the label data into a two-dimensional data set; constructinga multilayer two-dimensional convolutional neural network based on Attention, and training the multilayer two-dimensional convolutional neural network by using the two-dimensional data set in the previous step; For to-be-segmented and classified MRI image data of the myocardial part, collecting medical images of the same mode of the same part, and carrying out standardization processing on the collected images; and performing automatic segmentation and classification on the to-be-segmented and classified MRI image data of the myocardial part through the trained network model. According to theinvention, automatic segmentation and classification of the expansive myocardial region can be realized, and higher precision can be obtained in comparison with a mainstream network.

The invention provides mesenchymal stem cell injection, as well as a preparation method and application in preparing a medicament for treating children dilated cardiomyopathy. The mesenchymal stem cell injection comprises 2*10<5>-1*10<7> mesenchymal stem cells in every milliliter, clinical grade DMSO (dimethylsulfoxide) with volume ratio of 5 to 8 percent, human albumin with mass volume ratio of 1 to 6 percent, and multi-electrolyte liquid. The mesenchymal stem cell injection is prepared from placenta and umbilical cord, has the advantages of being high in yield, and being easy to realize industrialization, the preparation system quality is easy to control; the injection can be directly frozen through program-controlled freezing procedure and directly used in clinical injection after being recovered, and is safe and reliable. According to the injection, the dilated cardial structure can be changed, the function of heart can be recovered, the water supply state of each tissue in the whole body can be improved, the living quality of a patient can be improved, and the dilated cardiomyopathy can be treated fundamentally, so that the patient can get rid of serious complications caused by massive medicine administration, living action limitation and poor disease control.

The invention provides a Chinese medicine composition for treating dilated cardiomyopathy, belonging to the field of Chinese medicines. The composition is prepared from the following raw materials in parts by weight: 16 parts of Radix Paeoniae Rubra, 10 parts of Salvia miltiorrhiza Bunge, 10 parts of allium macrostemon, 10 parts of pericarpium trichosanthis, 9 parts of radix pseudostellariae, 20 parts of radix rehmanniae, 12 parts of Rhizoma Atractylodis Macrocephalae, 9 parts of plantain seed, 10 parts of Indian buead, 9 parts of radix aconiti carmichaeli and 10 parts of cassia twig. The Chinese medicine composition is prepared by taking natural traditional Chinese medicines as raw materials, so that combined action of traditional Chinese medicines is used for treating the dilated cardiomyopathy; all traditional Chinese medicines are combined to use; the application of the Chinese medicine composition is increased or decreased for treatment in accordance with condition of a patient; and the effect of the Chinese medicine composition is provided with synergy, thereby being harmless to human bodies.

The invention discloses a DNA library for detection of hereditary cardiomyopathy causing gene mutation through the targeting high-flux semiconductor sequencing technology and application thereof. Specifically, a primer pool is designed according to 80 hereditary cardiomyopathy causing genes, super-multiple PCR amplification is performed on sample genome DNA, and an amplified product is sequenced through the high-flux semiconductor sequencing technology to find pathogenic mutation so as to provide genetic and molecular biological theoretical bases for clinical diagnosis. The DNA library has the advantages of being accurate, quick, flexible and low in cost; through 80 gene detection areas related to the DNA library, five kinds of common hereditary cardiomyopathy including hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy and left ventricular myocardial densification incomplete cardiomyopathy can be detected, and the DNA library has an important meaning and clinical value for diagnosis and differential diagnosis of the hereditary cardiomyopathy.

The invention discloses an application of a traditional Chinese medicine composition in the preparation of a medicine for treating dilated cardiomyopathy. The traditional Chinese medicine composition of the invention achieves the aim of treating dilated cardiomyopathy by improving the heart function effectively and improving the ventricular remodeling to a certain extent.

A method for screening a substance that inhibits the onset of anti-cardiac troponin I autoantibody-related disease, a pharmaceutical composition and a base material for therapy of cardiac disease that contains the substance obtained by aforesaid method thereof, a therapeutic apparatus that removes anti-troponin I autoantibody for aforesaid antibody related disease, a method of making an animal model for evaluating cardiac disease characterized by administrating anti-cardiac troponin I antibody, a method of selection of a therapeutic substance for cardiac disease characterized by using aforesaid animals, and a diagnosis of dilated cardiomyopathy characterized by measuring anti-cardiac troponin I autoantibody. An apparatus of the present invention that removes anti-cardiac troponin I antibody and a pharmaceutical composition for therapy of the antibody related disease may be useful for a therapy and / or prevention of cardiac disease.

The invention discloses a pure traditional Chinese medicine preparation for treating dilated cardiomyopathy, which is prepared from astragali, radix salviae miltiorrhizae, red peony root, root-bark of peony, radix rehmanniae and the like as raw materials by steps of decocting twice, decocting filtrate, concentrating, granulating and packing in composite membrane bags. Shown by pharmacodynamic experiments of animals and clinical statistical results of patients, the pure traditional Chinese medicine preparation for treating dilated cardiomyopathy has the efficacies of supplementing qi, activating blood circulation, detoxifying and tranquilizing mind, and can eliminate the symptoms of chest distress, short breath, palpitation, edema, vexation, dark red tongue, yellow fur of tongue, thready rapid pulse, intermittent pulse and the like caused by deficiency of qi, blood stasis, toxic heat and heart disturbance due to dilated cardiomyopathy. The pure traditional Chinese medicine preparation can effectively resist myocardial fibrosis, improves the anoxia tolerance ability of myocardial cells and can be safely taken for a long time without toxic or side effect, the total effective rate in treating the dilated cardiomyopathy is 96.6%, and the curative effect is obviously better than that of conventional simple treatment of Western medicine.

The present invention provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having or at risk of having diabetic cardiomyopathy a therapeutically effective amount of a glycogen phosphorylase inhibitor. The present invention also provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having 1) diabetes and 2) having cardiovascular disease, ischemic heart disease, congestive heart failure, congestive heart failure but not having coronary arteriosclerosis, hypertension, diastolic blood pressure abnormalities, microvascular diabetic complications, abnormal left ventricular function, myocardial fibrosis, abnormal cardiac function, pulmonary congestion, small vessel disease, small vessel disease without atherosclerotic cardiovascular disease or luminal narrowing, coagulopathy, cardiac contusion, or having had or at risk of having a myocardial infarction a therapeutically effective amount of a glycogen phosphorylase inhibitor.

Genomically modified livestock animals having a modification in one or more genes implicated in heart failure are provided. The animals provide models for various pathologies in heart failure including dilated cardiomyopathy and hypertrophic cardiomyopathy and can be used for investigation of new treatment methods including interventional devices, biologics and pharmaceuticals. The models can also be induced to develop metabolic syndrome (MetS) and are therefore amenable to further investigation of the confounding effects of MetS on the progress of heart failure.

The invention provides a Chinese medicinal composition for treating dilated cardiomyopathy. The Chinese medicinal composition comprises the following components in part by weight: 5 to 7 parts of ginseng, 28 to 32 parts of astragalus, 12 to 18 parts of aconite, 12 to 18 parts of large-head atractylodes rhizome, 12 to 18 parts of tuckahoe, 12 to 18 parts of umbellate pore fungus, 9 to 15 parts of cassia twig, 12 to 18 parts of red-rooted salvia root, 28 to 32 parts of motherwort herb, 12 to 18 parts of pepper weed seed, 9 to 15 parts of lily-turf and 5 to 7 parts of Chinese magnoliavine fruit. Compared with the prior art, the Chinese medicinal composition is used for treating dilated cardiomyopathy aiming at internal pathogenic factors according to syndrome differentiation, is quick in curative effect, low in cost and obvious in effect, does not have toxic or side effect, and addresses both the symptoms and root causes.

The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and / or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.

The invention relates to a new mutant protein related to dilated cardiomyopathy, a new mutant gene and application thereof, discloses a mutant protein and a mutant TTN gene, has c.20292-20293 heterozygosis deletion variation compared with a human TTN gene, verifies that the mutation is related to dilated cardiomyopathy through research data, and protects the mutant protein and the gene based on arequest. And a kit for detecting dilated cardiomyopathy is disclosed. The mutant TTN gene provided by the invention can distinguish patients with dilated cardiomyopathy from normal people, and can beused as a biomarker for clinical auxiliary diagnosis of dilated cardiomyopathy. Carriers of the variation can be screened in the early stage, and prenatal and postnatal guidance and genetic counselingare provided for subjects. And a possible drug treatment target is provided for human to overcome the dilated cardiomyopathy.

The invention discloses application of a Chinese medicinal composition in preparation of a medicament for treating diabetic cardiomyopathy. The Chinese medicinal composition consists of 11 gouts of Chinese medicaments such as astragalus, ginseng, root of red rooted salvia and the like. The medicaments for tonifying qi and warming yang are used as radical components for treating channels and strengthening heart, and the medicaments for promoting blood circulation and removing obstruction in channels are used as auxiliary medicaments, so the qi is vigorous, the blood is activated, the channels are dredged, and blood stasis and channel obstruction are blocked. Experiment researches prove that the Chinese medicinal composition can effectively treat the diabetic cardiomyopathy.

The invention relates to an establishing method and application of a dilated cardiomyopathy and zebrafish disease model. A disease model simulating human congenital dilated cardiomyopathy (CDCM) is firstly established; and the disease model can be used as a drug screening model to be applied to screening of drugs capable of relieving symptoms of heart failure caused by CDCM. The method provided by the invention is an economic and rapid high-content screening method; and the obtained compound has relatively high specificity and druggability.